Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’

Published byEdgar Phillips Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’"— Presentation transcript:

1 Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’ schedule) for six planned courses. From: Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma Ann Oncol. 2012;24(4): doi: /annonc/mds531 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please 1

Download ppt "Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’"

Similar presentations

From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Figure 1 The spatial and temporal distribution of diarrhoea rates

Figure 1 The spatial and temporal distribution of diarrhoea rates
From: Global Banking: Recent Developments and Insights from Research*

From: Global Banking: Recent Developments and Insights from Research*
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Fig. 1 Graphical representation

Fig. 1 Graphical representation
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
Figure 2 Effects of political reforms on tariff reduction and political approval rating. From: TPP negotiations and political economy reforms in Japan’s.

Figure 2 Effects of political reforms on tariff reduction and political approval rating. From: TPP negotiations and political economy reforms in Japan’s.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)

Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)
Source:Ellerman, Convery, and de Perthuis (2010). Figure 6. 2, p

Source:Ellerman, Convery, and de Perthuis (2010). Figure 6. 2, p
pSS: primary SS; Scl: scleroderma.

pSS: primary SS; Scl: scleroderma.
Figure 6 Case 6: (A) MRA showed occlusion of the left internal carotid artery. (B) MRI 4 days before cell injection and (C) 7 days after cell injection.

Figure 6 Case 6: (A) MRA showed occlusion of the left internal carotid artery. (B) MRI 4 days before cell injection and (C) 7 days after cell injection.
Figure 1. Logos appearing in the choice experiment

Figure 1. Logos appearing in the choice experiment
Figure 1. Selection of papers.

Figure 1. Selection of papers.
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1 Individual Lifted from Group Photograph

Figure 1 Individual Lifted from Group Photograph
Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Similar presentations

Ads by Google